The time from Clonality (ID) test to first Tracking (MRD) test is usually within 3 months for patients with ALL.
When is clonoSEQ being implemented for patients with ALL?
Initiation of clonoSEQ MRD testing will vary based on a patient’s presentation and treatment course. For most ALL patients, the first Tracking (MRD) will be evaluated within 3 months of diagnosis*, and more than 85% of clonoSEQ-tested patients will have had their first MRD test within a year of diagnosis.
*Assumes ID collection date is indicative of time of diagnosis
Months after diagnosis that HCPs initiate clonoSEQ MRD Testing in ALL
This page is intended for use by healthcare professionals of the United States.
clonoSEQ® is available as a FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) , and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-validated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technicalsummary.